Author's response to reviews

Title: Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

Authors:

Maria Landqvist Waldö (Maria.Landqvist@med.lu.se)
Alexander Frizell Santillo (Alexander.Santillo@med.lu.se)
Ulla Passant (upas49@hotmail.com)
Henrik Zetterberg (Henrik.Zetterberg@clinchem.gu.se)
Lars Rosengren (Lars.rosengren@vgregion.se)
Christer Nilsson (Christer.Nilsson@med.lu.se)
Elisabet Englund (Elisabet.Englund@med.lu.se)

Version: 3 Date: 2 April 2013

Author's response to reviews: see over
Author's response to review:

Title: Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

Authors:
Maria Landqvist Waldö (maria.landqvist@med.lu.se)
Alexander Frizell Santillo (Alexander.santillo@med.lu.se)
Ulla Passant (upas49@hotmail.com)
Henrik Zetterberg (henrik.zetterberg@clinchem.gu.se)
Lars Rosengren (lars.rosengren@vgregion.se)
Christer Nilsson (christer.nilsson@med.lu.se)
Elisabet Englund (elisabet.englund@med.lu.se)

Version: 3 Date: 02 April 2013
Reviewer’s report

**Title:** Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

**Version:** 2 **Date:** 24 January 2013

**Reviewer:** John Ringman

**Reviewer’s report:**

Minor essential revision:

In the abstract, the Conclusion indicates that the highest levels of NFL were found in SD and that they were intermediate in the bvFTD cases. However, this specific result is not presented in the Results section. That the levels of NFL in SD > bvFTD > others should be specifically stated in the Results section.

Thank you for pointing this out. We added a sentence in the Result section (highlighted in yellow in the document) that fits with the statement in the abstract and the Discussion.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:** I have no conflict of interest with this article.

**Author’s revision:**

In order to further clarify our material and the two types of patient groups, we rephrased the Legends of Tables 2 and 3, the changes highlighted in yellow.